← Leaderboards
Miriam Komaromy
Rand Corporation
$7,902,571
Attributed
$15,805,142
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.2M · FY2019–24$20M$15M$10M$5M$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,805,142 · 1
By mechanism
UF1$15,805,142 · 1
Top collaborators
- Katherine E Watkins5 shared
Most similar at Rand Corporation
Same institution · by research overlap
- Lisa Seidel Meredith$9,200,580
- Katherine E Watkins$23,456,814
- Glenn John Wagner$20,840,440
- Allison Ober$4,010,165
- Itai Danovitch$2,907,786
Research focus
Post-Traumatic Stress DisordersCaringNew MexicoSecondary OutcomeImprove AccessLinkCollaborative CareMortalityOpioid Use DisorderDual DiagnosisMental DisordersOpioidMental DepressionMental HealthAddictionContextual FactorsAlcoholsMediatingComorbidityMedicalBehavioral HealthClinicHealth PersonnelDeath Rate
Grant awards (5)
Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness$1,800,000
UF1 · FY2024 · MH
Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness - Recruitment Extension$721,276
UF1 · FY2022 · MH
Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness$80,477
UF1 · FY2022 · MH
Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness$1,970,462
UF1 · FY2020 · MH
Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness$11,232,927
UF1 · FY2019 · MH